All News

Article

Digital Platforms and AI

2026 EULAR Press Release Jun 04, 2026

EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.

@RheumNow WIN Nutrition session at #EULAR2026 (3) 6.🍟 High UPF intake → increased RA risk (HR 1.06/SD), partly mediated by CRP. Not all NOVA-4 foods are equal 7.💊 Vit D supplementation significantly reduces SLE disease activity — MA of 10 RCTs, SMD −0.54 (p<0.00001). @RheumNow

WIN Nutrition session at #EULAR2026 (2) 🐟 n-3 PUFAs reduce RA risk by 9–10% per SD increase — especially in genetically high-risk individuals. 🫒 Mediterranean diet reduces RA risk by 25% (HR 0.75) & SLE risk by 39% (HR 0.61) in UK Biobank studies. @RheumNow

WIN Nutrition session at #EULAR2026 (1) 🫐Higher fruit intake → RR 0.88 & cereal intake → RR 0.87 for RA onset 🥩 Highest quartile of red & processed meat intake → nearly DOUBLE the risk of RA onset (OR 1.92, CI 1.11–3.35) @rheumnow https://t.co/RhO08FXtLI

https://x.com/Nellziade/status/2062496633867165972/photo/1

COMPARE Ph I trial CD19 CAR T-cell ACPA+ refractory RA 6 pts median 6.5 b/tsDMARDs Single CAR T infusion after lymphodepletion Safety -CRS only grade 1–2 (no severe events) -No ICANS -Transient neutropenia -No unexpected toxicities Efficacy DAS28-CRP ↓ ~41% median 50% achieved https://t.co/cdEfGKcJUp

https://x.com/AurelieRheumo/status/2062491277191438681/photo/1

D2T RA shows a linked brain–psychology–immune signature Cohort D2T RA vs non-D2T RA vs HC 91% D2T RA Higher catastrophizing Higher pain sensitivity More emotion-focused coping strategies “Chronic pain-like” profile Associated with higher CNS related gene expression NRG1 https://t.co/nkQco73vqI

https://x.com/AurelieRheumo/status/2062489005208334506/photo/1

Oral GLP1s now coming to the market-Peptide based (can be given only on empty stomach), Non peptide based (can be given anytime). Know about s/e and contraindications. May have Rheumatic diseases indications soon. Imp for rheumatologists to be familiar. #EULAR2026 @RheumNow https://t.co/KNudYN29PT

Sad to see this but important to be aware. Increasing risk of suicide using colchicine in Familial Mediterranean Fever. #POS0768 #EULAR2026 @rheumnow. Average age 28! 87%female, only 7 % with psychiatric referral! Retrospective 15 pts. https://t.co/241SE6O395

#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh

https://x.com/DrMiniDey/status/2062485261921964380/photo/1

Impt pts to consider in D2T CLE by Prof Wittmann: If tx is not working, ask yourself: is the dx correct? adherence? Main message: treat early When damage is present, tx doesn’t really provide considerable improvements Future drxns? Endotype-directed tx @Rheumnow #EULAR2026 https://t.co/hB48aD7jx5

#OP0240 phase 3 data showed that the pan-JAK inhibitor gecacitinib significantly improved disease activity, function, MRI inflammation and quality of life in active radiographic axSpA versus placebo at 16 weeks, with ASAS40 responses of 51.9% vs 12.9%. #EULAR2026 @RheumNow https://t.co/6oojvvFmk0

https://x.com/DrMiniDey/status/2062483752043872563/photo/1

Weight management should be discussed!! Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist. Best evidence in OA and Gout. #EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu

https://x.com/bella_mehta/status/2062483715142426830/photo/1

Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow Inflammation triggered by metabolic abnormalities. This may be the reason a lot of our inflammatory arthritis patients on GLP1 drugs(other indications) have thier disease activities improving. Emerging data.

#OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high specificity but lower sensitivity than 2009 criteria, reflecting greater emphasis on imaging & less reliance on clinical features alone. #EULAR2026 @RheumNow

Catching your breath session at #EULAR2026 RA-ILD is heterogeneous, maybe under-recognized and risk stratification remains a challenge (Pierre-Antoine -Jugr) Screening for RA-ILD is only as good as availability of early intervention and treatment (Jeff Sparks) @RheumNow https://t.co/V1JXM3i9wP

Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.

EULAR 2026: Industry Press Releases Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will https://t.co/2czkdWKtEO

Why are GLP1 agonists important in rheumatology- plenary at #EULAR2026 Presence on leucocytes- change from pro inflammatory to anti inflammatory casade Also in fibroblasts in rheumatoid arthritis. Trials on the way for OA, Gout, as well as IBD. @RheumNow https://t.co/WJ6actAzrv

#OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower overall cancer risk vs shorter exposure, esp for haematologic malignancies. Data add to long-term safety evidence for targeted therapies in SpA. #EULAR2026 @RheumNow

#OP0237 reports positive phase 3 data for the selective JAK1 inhibitor ivarmacitinib in active nr-axSpA. ASAS40 responses at Week 12 significantly higher vs placebo (39.7% vs 24.8%), with sustained efficacy through Week 24 and no new safety signals observed. #EULAR2026 @RheumNow https://t.co/JZLQ0Ywlio

https://x.com/DrMiniDey/status/2062479473879261672/photo/1

Topics

All News

Digital Platforms and AI

Do you get our email newsletter?